Skip to main content

Table 2  Demographics details, clinical data, and laboratory data according to the occurrence of acute kidney injury during ICU stay

From: Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy

 

Acute kidney injury

p

No ( N = 30)

Yes ( N = 123)

Age (years)

48.50 (31.50–64.75)

63.00 (50.50–70.00)

0.004

Male

12 (40.0)

93 (75.6)

 < 0.001

G6PD deficiency

1 (3.3)

8 (6.5)

0.819

Underlying malignancy

  

0.452

 Solid cancer

0 (0)

2 (2.3)

 

 Leukemia

13 (43.3)

39 (31.7)

 

 Non-Hodgkin lymphoma

17 (56.7)

73 (59.3)

 

 Multiple myeloma

0 (0.0)

2 (1.6)

 

 Other

0 (0.0)

7 (5.7)

 

 Spontaneous TLS

12 (40.0)

78 (63.4)

0.033

 Nephrotoxic use

6 (20.0)

48 (39.0)

0.082

Cardiovascular risk

   

 Chronic hypertension

5 (16.7)

41 (33.3)

0.118

 Diabetes

2 (6.7)

17 (13.8)

0.449

 Cardiovascular event

2 (6.7)

13 (10.6)

0.763

 Chronic kidney disease

2 (6.7)

8 (6.6)

1.000

 HIV positive status

1 (3.3)

25 (20.3)

0.051

 mSOFA score

4.00 (2.00–4.75)

5.00 (2.00–7.00)

0.021

 Vasopressors

1 (3.3)

23 (18.7)

0.073

 Mechanical ventilation

2 (6.7)

32 (26.0)

0.041

 Rasburicase use

24 (80.0)

90 (73.2)

0.592

Laboratory data at admission

   

 Kalemia, mEq/L

4.10 (3.70–4.70)

4.60 (4.00–5.00)

0.084

 Phosphatemia, mg/dL

3.53 (2.82–4.37)

4.71 (3.49–6.18)

0.003

 Calcemia, mg/dL

8.94 (8.17–9.48)

8.68 (7.80–9.44)

0.421

 Uricemia, mg/dL

6.84 (5.38–9.32)

8.78 (5.17–13.10)

0.166

 LDH, UI/L

2700 (2008–4630)

2855 (1466–5286)

0.925

ICU mortality

3 (10.0)

24 (19.5)

0.338

One-year mortality

11 (36.7)

75 (61.0)

0.028

One-year remission

16 (53.3)

38 (30.9)

0.036

  1. Results are reported as n (%) or median (IQR)
  2. G6PD glucose 6 phosphate dehydrogenase, TLS tumor lysis syndrome, HIV human immunodeficiency virus, mSOFA modified Sequential Organ Failure Assessment, LDH lactate dehydrogenase, ICU intensive care unit